drugset / Trial / NCT03475004
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, single-center, single-arm phase II clinical trial evaluating the combination of pembrolizumab, binimetinib, and bevacizumab in patients with metastatic colorectal adenocarcinoma who have not responded to prior therapy.
Timeline
- Start
- 2018-09-17
- Primary completion
- 2022-04-14
- Completion
- 2024-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Binimetinib | Small molecule | 15 mg | Oral |
| Subject | Binimetinib | Small molecule | 30 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |